NICK GREEN
Former CEO/PRESIDENT
AVID BIOSERVICES
WHY: Spearheaded pivot from failed clinical developer of cancer drugs to being a full-time drug contract manufacturer, more than tripling size of firm since joining in 2020.
IN THE NEWS: Avid went private earlier this year via a $1.1B sale to private equity firms GHO Capital Partners LLP and Ampersand Capital Partners.
NOTABLE: Stepped down as CEO in September. Succeeded by Kenneth Bilenberg, former CEO of FujiFilm Diosynth Biotechnologies.
QUOTABLE: “It’s certainly not a one man show. A lot of people put a lot of work, time and effort creating what we’ve got today.”
